Remove 2004 Remove 2020 Remove Marketing Remove Metrics
article thumbnail

7 Strategies To Solve Your Business Problems Faster

Startup Professionals Musings

A broken process or a subtle quality issue can generate a flood of customer satisfaction problems, cost overruns, and loss of market share. Way back in 2004, he cared enough about an associate's injury to spend time investigating, and used the exercise to isolate a root cause without blaming anyone. Don’t waste time fixing symptoms.

Dividend 382
article thumbnail

State of VC 2.0

View from Seed

Warning – this assumes some basic knowledge of VC performance metrics. Will Quist did a great job of explaining this market rhetoric in this thread. The three-question framework goes as such: Q: How much tech-related market cap will be created in the next 10-20 years? Ok, let’s jump in. State of VC: are we in a bubble?

Valuation 319
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

State of VC 2.0

View from Seed

Warning – this assumes some basic knowledge of VC performance metrics. Will Quist did a great job of explaining this market rhetoric in this thread. The three-question framework goes as such: Q: How much tech-related market cap will be created in the next 10-20 years? Ok, let’s jump in. State of VC: are we in a bubble?

Valuation 295
article thumbnail

State of VC 2.0

View from Seed

Warning – this assumes some basic knowledge of VC performance metrics. Will Quist did a great job of explaining this market rhetoric in this thread. The three-question framework goes as such: Q: How much tech-related market cap will be created in the next 10-20 years? Ok, let’s jump in. State of VC: are we in a bubble?

Valuation 156
article thumbnail

When Entry Multiples Don’t Matter

Ben's Blog

While multiples are indeed often an input for valuing mature, slower growing companies, in the private, high growth tech market, entry multiples tend to be a byproduct of the valuation process: What investors are really trying to understand are possible exit values. A multiple is a company value divided by a metric.

article thumbnail

Out of the Crisis #5, ANA Therapeutics: a possible COVID-19 treatment and prophylactic

Startup Lessons Learned

And so, when we said that jokingly, Nadja diligently started going through the literature research, and in five minutes pulled up a paper saying, "Well, here's a paper that shows that during the SARS outbreak in 2004, niclosamide was actually a very potent inhibitor of viral replication." But I think that, again, this is hindsight being 2020.